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Abstract 
 
Purpose 
To review the pathogenesis of uveitis in light of recent advances in our 
understanding of innate and adaptive immune responses and their regulation. 
 
Design 
A perspective.  
 
Methods 
 The methods included a review of prevailing views on the pathogenesis of 
uveitis, and an analysis of developments in immunology which impact on its 
conceptual basis, particularly the concept of immunological tolerance and its loss in 
autoimmunity. Importantly, the role of infection in the pathogenesis of uveitis is 
evaluated. 
 
Results  
 The results comprise a re-appraisal of the pathogenesis of anterior versus 
posterior uveitis in the context of the blood-retinal barrier and its relation to 
autoimmune, auto-inflammatory and infectious uveitis. Autoimmunity is seen as a 
possible cause of certain forms of uveitis but definitive proof is lacking. Auto-
inflammatory disease, involving activated innate immune mechanisms, is considered 
causative in a second set of uveitis conditions. A place for infection in uveitis 
generally is proposed within a unifying concept for the pathogenesis of uveitis.  
 
Conclusion 
 Infection may be implicated directly or indirectly in many forms of non-
infectious or undifferentiated uveitis. In addition to the growing recognition that 
foreign antigen, including re-activatable infectious agents, might hide within ocular 
tissues, the possibility that a dysregulated microbiome might generate T cells which 
cause immune-mediated ocular inflammation has now been demonstrated 
experimentally. An uncontrolled, over-exuberant host immune response may cause  
continuing irreversible tissue damage even after the infection has been cleared. 
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 Uveitis is a threat to vision, either directly or through ocular complications 
1
. 
With a prevalence of 115-204 /100,000 population and incidence of 17-52 new cases 
/ 100,000 per year in Northern California, uveitis is infrequent but because it affects 
all age groups carries a significant socio-economic burden 
2
. Uveitis specialists 
categorize uveitis etiologically as either infectious or non-infectious 
3
.  Infections are 
proven causes of some cases of uveitis 
4-7
.  In others, activation of innate immune 
processes in response to infection may cause tissue damage through a mechanism of 
autoinflammation.   
Non-infectious uveitis is not synonymous with autoimmune uveitis. The 
autoimmune hypothesis for non-infectious uveitis derives from experimental models 
of retinal inflammation that create blood-retinal barrier breakdown and stimulate 
adaptive immunity directed toward retinal antigenic targets. In non-retinal tissues, 
autoinflammatory or innate immune-mediated mechanisms may prevail. Because 
infectious agents usually drive autoinflammation, infection may underlie the 
pathogenesis of most uveitis, either through cytolytic tissue damage or through 
uncontrolled and dysregulated host immune responses that continue after infection 
subsides.  
This perspective discusses evidence to support the concept that infection 
may be more and autoimmunity less involved in the pathogenesis of uveitis.  
 
Key role of blood retinal barrier in understanding the pathogenesis of uveitis 
 
 Uveitis as a universal term is not accurate regarding pathogenesis as other 
ocular components are often the inflammatory target. However, the uvea is 
consistently involved in intraocular inflammation, transporting more than 80% of the 
ocular blood volume, as well as managing the bulk flow of aqueous fluid 
8
. The 
clinical classification of uveitis based on anterior, intermediate, posterior or 
panocular location 
3
 is insufficient when considering the pathogenesis of uveitis, 
which depends on whether the blood retinal barrier (BRB) is breached. Uveitis may 
be restricted to tissues external to the BRB, encompassing iritis, cyclitis, keratouveitis, 
sclerouveitis, and choroiditis, or uveitis may affect tissues normally protected by the 
BRB, including retinitis, retinal vasculitis, retinochoroiditis, and optic neuritis. In 
pathogenetic terms, posterior uveitis involves breakdown of the BRB while other 
forms of uveitis do not. Inflammation that involves compromise of the BRB is always 
associated with inflammation of the uveal tract but the reverse is not true. This 
distinction helps us to understand the etiology of uveitis. 
 
Is non-infectious uveitis autoimmune? 
  
   
Autoimmunity has been proposed as the pathogenesis for non-infectious 
uveitis 
9
, paralleling the accepted pathogenesis of other organ specific autoimmune 
diseases 
10, 11
.   
 In principle, an autoimmune disease requires the identification of an 
autoantigen and an experimental model which resembles human disease 
12
. 
Although both lens protein and uveal pigment have been proposed as potential 
autoantigens 
13
 extensive experimentation with uveal extracts has failed to produce 
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a reliable animal model that mirrors human uveitis. The retina contains several 
potent autoantigens that are expressed in the thymus 
14
 and in secondary lymphoid 
tissue 
15
 where immunological tolerance and prevention of autoimmune disease is 
maintained by a range of mechanisms, including clonal deletion and anergy. Genetic 
defects in the autoimmune regulator (AIRE) gene 
16
  are known to cause 
experimental and clinical autoimmune diseases, including a form of posterior uveitis 
17
. Regulatory T cells (Treg) also maintain self-tolerance and control immune 
responses 
18, 19
, including those in the retina 
20, 21
. Autoimmunity to retinal 
autoantigens can be induced in several animal models including primates 
17
. 
Experimental autoimmune uveitis (EAU) is considered a classical organ specific 
autoimmune disease that resembles posterior uveitis in man 
22
. Despite the many 
insights that EAU reveals about into mechanisms of tissue damage in posterior 
uveitis, the model is difficult to translate to the wide range of human uveitic entities. 
 In EAU, there is extensive breakdown of the BRB 
23, 24
 with release of retinal 
autoantigens.  Depending on context, these have the potential to activate the small 
number of self-antigen reactive T cells that have escaped thymic deletion and 
circulate in the periphery 
15
. Accordingly there is a marked expansion of autoreactive 
T cells and autoantibodies to retinal antigens that can be detected in mice with EAU. 
Similar cellular or humoral immunological evidence is required to define 
autoimmune uveitis in humans. However, despite genetic conditions such as 
autoimmune polyendocrinopathy-candidiasis–ectodermal dystrophy/dysplasia  
 (APECED) 
16
, evidence for autoimmunity in undifferentiated non-infectious uveitis is 
sparse. Some clinical entities which are linked closely with restricted MHC genetic 
types such as Vogt-Koyanagi-Harada (VKH) disease 
25
, sympathetic ophthalmia 
26, 27
 
and birdshot retinochoroidopathy (BRC) 
28
 have the strongest claim to be bona fide 
autoimmune diseases. Of these, BRC may resemble diabetes mellitus as a potential 
CD8 T cell-mediated autoimmune disease in which presentation of cryptic peptide 
determinants of retinal S antigen 
29
 could theoretically be enhanced by presentation 
via HLA A29 
30
.  
 Several studies have demonstrated that both humoral and cellular responses 
to a range of retinal antigens and their epitopes occur in patients with either 
infectious or undifferentiated uveitis 
31-33
. Results have been inconsistent and self-
reactivity to retinal antigens has been observed in healthy individuals 
32, 34-37
. Similar 
confounding results have been observed in non-ocular diseases, and the number of 
definitive autoimmune diseases, in which autoreactive T cells or autoantibodies have 
been shown to be pathogenic, is limited. In addition, restoration of immunological 
tolerance in patients with diseases such as multiple sclerosis, rheumatoid arthritis 
and uveitis, although clearly effective in experimental models 
38
 that use 
experimental therapies such as mucosal tolerance induction, has not yet reached the 
clinic 
39
.  
 Alternatively, a reduction in Tregs has been viewed as evidence that 
regulation of autoimmunity is impaired. However, the situation is complex. 
Circulating Tregs may be reduced in active disease but paradoxically may be 
increased in the tissues in both uveitis and rheumatoid arthritis 
40
. The plasticity of 
Tregs and their possible interconversion with pathogenic T cells has also not helped 
to define immunoregulatory mechanisms 
41
.  In addition, because Tregs can control 
immune responses to both autoantigens and infectious agents 
18
 their involvement 
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does not help to differentiate autoimmune disease from post-infectious immune-
mediated disease. 
 The above observations do not exclude autoimmune pathogenesis. For 
instance, autoimmune pathology may be part of a dual process arising later in 
disease evolution, such as via bystander damage in which release of autoantigen 
during an infectious condition leads to activation of autoreactive T cells. Indeed most 
recently, peptide therapy with the autoantigenic peptide, proinsulin in patients with 
early Type1 diabetes has been shown to delay progression of disease as measured by 
insulin requirement 
42
. Perhaps a consistently identifiable target retinal autoantigen 
might allow a peptide therapy approach for secondary autoimmunity in human 
uveitis.   
 
Is non-infectious uveitis autoinflammatory? 
 
 Autoinflammation and autoinflammatory disease are relatively recent 
concepts based on observations that patients with monogenic disorders affecting 
innate immune cells (predominantly myeloid cells such as macrophages and 
neutrophils) developed discrete syndromes, such as TNF-receptor associated 
periodic syndrome (TRAPS) and familial Mediterranean fever (FMF) (Table 1). Innate 
immune cells are central to classical autoimmune diseases due to their essential role 
in generating adaptive immunity (described by Janeway as “the immunologist’s dirty 
little secret” 
43
). Animal models of autoimmunity, including EAU, require a bacterial 
adjuvant to stimulate innate immune cells, particularly dendritic cells
44
, which in turn 
activate specific T cells 
45
. Pattern recognition receptors (PRR)  recognize classes of 
micro-organisms by interaction with molecular patterns on pathogens (PAMPs) and 
then generate a range of T cells including Th1, Th17, Th9 ordinarily thought of as 
parts of the adaptive immune system 
46
. 
 TRAPS was the first reported auto-inflammatory disease in humans. Its 
defining features are episodes of unprovoked ocular, periocular, and skin 
inflammation in the absence of high titres of autoantibodies or T cell responses. The 
condition results from spontaneous production of cytokines due to a missense 
mutation in p53, one of the proteins in the NF-kB complex 
47
.   Since then, several 
other auto-inflammatory conditions have been described (Table 1) and, as with 
discoveries relating to adaptive immunity, in which delineating the genetic defects in 
patients with T and B cell abnormalities revealed their physiological function 
48
, 
mutations in genes controlling innate immune pathways have greatly assisted our 
understanding of how innate immunity is structured. Several classes of PAMPs have 
now been discovered, which activate specific signalling pathways through PRRs for 
bacteria, fungi, viruses, parasites and other foreign organisms and when these 
pathways are spontaneously activated, or homeostatic control dysregulated, they 
cause autoinflammatory diseases (Table 1).  
 Since many cases of uveitis are episodic, unprovoked and lack good evidence 
for specific autoantibodies or T cell responses to support an autoimmune 
pathogenesis, it has been suggested that at least some forms of uveitis may be 
autoinflammatory. Many monogenic autoinflammatory conditions involve activation 
of the inflammasome and are characterised by the secretion of IL-1 or one of its 
related molecules 
49
. Importantly, skin /mucosal pathology in the form of vesicles or 
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ulceration is almost a common denominator. Uveitis features as part of the 
syndrome in several of these conditions 
50
 (Table 1). Moreover, the definition of 
autoinflammatory disease has been widening to an increasing list of complex genetic 
disorders, which includes Type 2 diabetes, macular degeneration and Behçet disease 
(Table 2).  
 A closer examination of uveitic conditions reveals some that might fit the 
description of autoinflammation in which there is evidence of activation of innate 
immune (myeloid) cells in the absence of a specific trigger. Some of these are 
polygenic systemic conditions in which uveitis may be part of the clinical 
presentation (Table 2). Candidate diseases include Behçet disease, JIA-associated 
anterior uveitis, pars planitis, intermediate uveitis, and tubulo-interstitial nephritis / 
uveitis (TINU) syndrome as well as others in which no auto-antigen has been 
identified, there are no representative animal models and clinical evidence for 
humoral or cell mediated autoimmunity is thin. In particular, the HLA B27-associated 
spondyloarthropathies, and presumably by association HLA B27-linked acute 
anterior uveitis, are considered by some to be autoinflammatory diseases [
51
] with a 
predisposition linked to protein misfolding and IL23 polymorphisms 
52
. Both anterior 
and posterior uveitis occur in Behçet disease which resembles an autoinflammatory 
disease by its predominantly neutrophil-mediated pathology 
53
. 
 Pathogenetically, it is unlikely that the full range of heterogeneous uveitis 
conditions can be attributed to autoinflammatory mechanisms. In this evolving field, 
unlabelled conditions with a positive response to blockade of IL-1 are preliminarily 
described as undifferentiated systemic autoinflammatory diseases (uSAIDs) 
54
. 
Similarly, non-infectious uveitis has been re-branded as undifferentiated uveitis to 
signifiy the lack of a clear etiology 
55
. In this context, uveitis associated with Behçet 
disease 
56
 and JIA has been reported to respond to anti-IL-1 therapy in small cohort 
studies. A larger study using the same criteria to investigate a range of non-Behçet 
posterior uveitis was inconclusive 
57
. Despite the current uncertainty, increasing 
knowledge of the molecular signatures of disease seems likely to improve our 
understanding of the heterogeneity of uveitis.  
 
Is non-infectious uveitis caused by infection?   
 
 Infectious agents have been implicated in the pathogenesis of autoimmune 
and autoinflammatory diseases generally. There is also a long-standing suspicion 
that the morbidity that results from many forms of ocular inflammatory disease 
derives from infection, either directly or by a dysregulated host response to infection. 
Non-infectious uveitis or undifferentiated uveitis is described as immune-mediated 
when no direct infectious cause can be identified but may in fact have been initiated 
by infection.  
   How infection might underpin the pathogenesis of uveitis relates to 
experimental models of autoimmune disease. Like most experimental models, EAU, 
a paradigmatic autoimmune disease 
17
, requires mycobacterial extract and pertussis 
toxin to prime autoantigenic (IRBP)-specific Th1 and Th17 T cells, which target the 
retina and cause the disease. The mycobacterial extract commonly used to induce 
EAU is H37Ra which is an attenuated form of Mycobacterium tuberculosis (MTb) 
cultured from tissue samples of a patient with active tuberculosis 
58
. MTb is rich in 
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PAMPS and activates the inflammasome and other pathways to release pro-
inflammatory cytokines such as IL12, 23, 27 and IL-1. IL-1, the major cytokine driving 
autoinflammatory disease (see above section) is required for EAU induction by 
activating DC 
59
. In contrast, tolerogenic DC which protect experimental mice against 
EAU, specifically fail to generate IL-1 when activated by MTb 
60
.    
 MTb is believed to have infected up to a third of the world’s population, the 
majority of whom remain latently infected, with a significant mortality rate 
61
. MTb is 
a major cause of uveitis in humans, both in developed and developing countries 
62, 63
 
and presents in a large variety of clinical phenotypes, some of which are included in 
the category undifferentiated or non-infectious such as atypical serpiginous 
choroiditis 
64
.  How might MTb cause ocular inflammation? During the initial 
infection in the lung, myeloid cells (macrophages and DC) are specific targets of MTb 
that either kill or are killed by the MTb. In other cells, MTb evades killing and become 
latent within the cell. Latently infected myeloid cells traffic in and out of granulomas 
65
 and recirculate to reside in extrapulmonary sites such as the kidney, dermis, 
muscle, lymph nodes, meninges, and uveal tract where they can be reactivated at 
later times. If the pathogen thrives, a severe local infection with tissue damage (e.g. 
caseation) ensues. However, if the pathogen is contained, as in an 
immunocompetent individual, an over-exuberant host immune response to the 
reactivated MTb might then cause severe immune-mediated damage. In addition, at 
extrapulmonary sites of tissue damage, MTb antigen released from dead cells might 
act as a local adjuvant to innate immune cells which stochastically interact with 
autoreactive T cells in a bystander fashion and cause a secondary autoimmune 
reaction. Recent evidence for this secondary autoimmune reaction in patients with 
tuberculous uveitis has been reported 
66
. 
 A link with infection or infectious material is difficult to identify in many cases 
either clinically and experimentally. For instance, spontaneous models of EAU occur 
in retinal antigen-specific T cell receptor transgenic mice without use of adjuvant 
67
. 
However, exposure to microbial antigen still appears to be necessary since EAU fails 
to develop in these mice if they are bred in germ-free conditions 
68
. In fact, even the 
standard model of IRBP / MTb-adjuvant-induced EAU cannot be induced in germ-
free mice
69
. Remarkably, it appears that commensal antigen from the bowel 
activates antigen specific T cells which traffic to the retina and cause disease. These 
observations have considerable significance for the long known association between 
IBD, uveitis, and the spondyloarthropathies. Interestingly, not all commensal antigen 
is harmful; some commensals appear to protect from uveitis and so the context, and 
possible association with dysbiosis, might determine whether infection-associated 
immune-mediated uveitis occurs 
70
. These clinical and experimental observations 
suggest that non-infectious, undifferentiated uveitis may be initiated by persistent, 
non-replicating micro-organisms or residual microbial antigen. The infectious 
etiology of chronic anterior uveitis caused by Propionbacterium acnes may not be 
immediately recognised. Similarly, recurrent chronic anterior uveitis due to herpes 
viruses often fails to yield active virus on investigation. Other forms of previously 
undifferentiated anterior and posterior uveitis are now recognised as being due to 
infection, such as hypertensive uveitis caused by CMV; Fuch’s heterochromic uveitis 
due to rubella; and Chikungunya, West Nile virus, Dengue, and Rickettsia as causes 
of retinal vasculitis.  
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 Much of the evidence for infection in these cases is not based on strict 
criteria of demonstrating replicating virus, but is simply based on viral DNA detected 
in ocular fluid or on serological evidence of a prior infection. As such, direct causative 
relationships between the infection and uveitis cannot be established but an 
adjuvant or, at least, an immune-meditated role whereby persistent antigen drives 
reactivation of resident memory T cells 
71, 72
, can be envisaged. Recurrent uveitis 
might thus result either from reactivated replicating infectious agent or from a re-
activated host immune-mediated response to an infectious agent. This has particular 
relevance, for instance, to uveitis associated with TB or toxoplasmosis where both 
anti-microbial therapy as well as immune-modulating agents may be required to 
minimise tissue damage but risk reactivating the latent micro-organism. In some 
cases viable replicating microbial agents have been demonstrated. The recent 
reports of late cultured virus from ocular and other tissue samples in patients who 
have recovered from Ebola, Zika and other viral infections indicate that viable virus 
persists in the tissues for long periods 
73-75
. 
 This may be a common mechanism for the pathogenesis of disease, namely 
that if the host survives the initial infection, and the infectious agent is not 
completely cleared, then, to varying degrees, the organism persists undetected 
either as a viable infectious agent or as a residual antigenic pool which allows 
recurrent immune-mediated recrudescence of anti-microbe and/or anti-host 
(bystander effect) tissue damage. Perhaps an “either-or” approach to the 
pathogenesis of uveitis in terms of infection is too restrictive and a greater role for 
pathogens either as a direct effect (infectious uveitis) or as the cause of a 
dysregulated host response to pathogens once they have either been cleared or 
become latent (non-infectious, undifferentiated uveitis) offers a more unified 
pathogenetic framework.   
 
Does the BRB regulate both infectious and non-infectious / undifferentiated 
uveitis? 
 As argued in the first section of this Perspective, the pathogenesis of 
posterior uveitis, affecting the retina and optic nerve, is different from uveitis 
affecting sites outside the BRB. Retinal and CNS antigens are protected from damage 
by the BRB, which in the immunocompetent, healthy individual prevents both 
invasion by infectious agents and the passage of potentially damaging immune cells. 
It does this through two mechanisms: a physical barrier composed of the tight 
junctions of the retinal blood vessels and the retinal pigment epithelium (RPE), and 
an immunological barrier formed by cells of the neurovascular unit (retinal 
endothelium, perivascular macrophages, pericytes, microglia and the foot processes 
of glial cells forming the glia limitans)
76, 77
 and by the RPE. The RPE in particular 
produces immunosuppressive mediators and, importantly, converts naïve T cells to 
Treg 
78-80
.  
 Immune regulation at the BRB applies both to infectious and non-infectious 
uveitis. For example, infectious forms of uveitis which occur outside the BRB such as 
CMV- and HSV-induced anterior uveitis do not involve the retina unless the patient 
has lost immune regulatory control at the BRB. Thus, a CD4 count <50 cells/ml in 
untreated AIDS patients allows unchecked viral replication and CMV retinitis. When 
the CD4 count rises above 50, viral replication and infection in the retina can be 
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controlled but if the Treg / Teffector 
81, 82
 cell ratio is not normalised, cell immune-
mediated uveitis ensues. Only if the BRB is physically broken or immunologically 
impaired as has been shown repeatedly in experimental animal models 
83
 can viral 
retinitis be induced.  
 The BRB presents both a physical and an immunological barrier to infectious 
agents and to circulating immune cells, and it serves in this capacity for both 
infectious uveitis in which damage is caused directly by the infecting agent, and non-
infectious immune-mediated uveitis in which an uncontrolled, dysregulated immune 
response is the cause. An appropriate immune response that adequately clears any 
infection is clearly desirable. Regulating the host cellular immune response to the 
infectious agent or to an autoantigen, before either the infectious agent or the tissue 
damaging immune cells can cross the BRB, is also essential. Most infectious agents, 
particularly viruses and parasites, are held in check by the BRB but have ready access 
to other ocular tissues and cause uveitis either by replicating in situ in the acute 
phase or by inducing chronic / recurrent immune-mediated inflammation. In 
contrast, infectious agents that manage to cross the BRB either cause massive 
replicative end-stage damage or become latent (as in toxoplasmosis) mainly due to 
effective immunoregulatory mechanisms of the retinal parenchymal 
microenvironment.   
 
Conclusion 
 
 There is a growing awareness that while examples of autoimmune and 
autoinflammatory mechanisms have been well described and may explain the 
pathogenesis of uveitis, many cases of idiopathic or undifferentiated uveitis may 
ultimately be seen to be initiated by infection. Chronic inflammation and tissue 
damage may be the result of an exaggerated or dysregulated host response to the 
infection and the microbiome might be a significant source of infectious antigen and 
antigen-specific T cells. Thus, chronic or recurrent uveitic disease may be caused by 
local reactivations of persistent microbial agents or inadequately cleared antigen, 
including retroviral antigen, which intermittently disrupt the Treg / Teffector cell 
ratio. In addition, a dysregulated microbiome may predispose to, or even be the 
source of uveitogenic pathogens or adjuvants. Indeed, it is also likely that periodic 
episodes of uveitis in monogenic autoinflammatory diseases are driven by microbes 
that would normally be harmless in immunocompetent individuals.   
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Table 1 
 
Title: Autoinflammatory Monogenic Disorders and Uveitis 
 
Condition Gene 
affected 
Mechanism Uveitis Ref 
Familial 
Mediterranean 
Fever (FMF) 
Pyrin (MEVF) Increased 
inflammasome 
activity 
yes 
84
 
HIDS * Mevalonate 
kinase 
Increased 
inflammasome 
activity 
Reviewed by 
Ter Haar 
85
 
Muckle Wells 
syndrome 
NLRP/cryopyrin Inflammasomopathy Yes 
86
 
CAPS * cryopyrin Inflammasomopathy yes 
87
 
TRAPS * TNF receptor 1 Protein misfolding ? (periocular 
inflammation) 
88
 
NOMID * NLRP / 
cryopyrin 
Inflammasomopathy Yes 
89
 
Blau syndrome NOD2 /CARD 
15 
NF-kB dysregulation Yes 
90
 
Pyoderma 
gangrenosum 
and acne 
91
 
PSTPIP1 / 
CD2BP1 
PSTPIP1  pyrin 
binding 
No   
Deficiency in 
IL-1 receptor 
antagonist  
5
 
IL-1RN Absence of IL-1Ra No  
Majeed 
syndrome 
Lipi2 (Lipin-2) ? NLRP regulation 
defect 
No  
HLH * UNC13D, 
perforin, 
syntaxin 
Macrophage 
activation 
Yes 
92
 
Gaucher’s 
disease 
GBA (acid 
glucosidase) 
? Yes 
93
 
Aicardi-
Goutier’s 
syndrome 
Trex gene Failure of cDNA 
sensing by RIG-1 
Chorioretintitis  
in Aicardi-like 
syndrome 
reported 
94
 
CANDLE 
syndrome 
PSMB8 Proteasome subunit 
defect 
yes 
95
 
 
Footnote: Uveitis, predominantly anterior, contributes the overall phenotype of  
several monogenic autoinflammatory disorders.  
 
* HIDS: hyperimmunoglubulinaemia D and periodic fever syndrome; CAPS: 
cryopyrin-associated periodic syndrome; TRAPS: tumor necrosis factor associated 
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periodic fever syndrome; NOMID: neonatal onset multisystem inflammatory disease; 
HLH: haemophagocytic lymphohistiocytosis  
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Table 2.  
 
Title: Multisystem disorders with possible autoinflammatory pathogenesis and 
their  association with uveitis 
 
 
Condition Gene(s) Mechanism Uveitis 
(ref) 
Systemic onset JIA ? ? macrophage activation 
and IL1A gene 
96, 97
 
Adult onset Still’s 
disease 
? ? overproduction of IL-
1beta 
 
Schnitzler syndrome ? sporadic Increased 
inflammasome 
activation 
 
Crohn’s disease NOD2/ATG16L1 IGRM NF-kB dysregulation 
98
 
CRMO* ? ? anti-IL6 responsive  
SAPHO * ? ? deficiency in FOXO1 
99, 100
 
Gout SLC2A(/GLUT9/ABCG2 crystallopathy 
101
 
Pseudogout ? crystallopathy  
Type 2 diabetes ? glucoseinflammasome 
activation 
 
Atypical haemolytic 
uremic syndrome 
CFH, CD46,CFI, CFB abnormal regulation of 
C3b 
 
Age-related macular 
degeneration 
CFH failed inactivation of 
C3b, inflammasome 
activation  
 
Behcet’s disease ? increased 
inflammasome 
activation 
102, 103
 
Atherosclerosis ? ? dysregulated 
macrophage activation 
 
Asbestosis ? particles 
inflammasome 
activation 
 
HLA B27 
spondyloarthropathies 
MHC Class I (B27) misfolded protein  
inflammasome 
activation 
104
 
 
 
Footnote: An increasing number of polygenic, multisystem diseases may have an 
autoinflammatory pathogenesis; uveitis, both posterior and anterior, are prominent 
features of some of these conditions 
 
 * CRMO: chronic recurrent multifocal osteomyelitis; SAPHO: synovitis-acne-
pustulosis-hyperostosis-osteitis 
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